Description

Vosoritide (BMN 111) CAS 1480724-61-5 is a meticulously engineered, recombinant analogue of C-type natriuretic peptide (CNP), optimized for stability and receptor engagement. Enhanced with N-terminal and C-terminal modifications, Vosoritide retains binding affinity for NPR-B (natriuretic peptide receptor B) while resisting proteolytic degradation, thereby prolonging half-life and enabling controlled dosing in experimental models.

Mechanistically, after binding to NPR-B on chondrocytes, Vosoritide activates intracellular cGMP signaling cascades. This leads to modulatory effects that counteract overactive FGFR3-driven growth plate inhibition, thereby promoting chondrocyte proliferation and endochondral ossification. As a result, it supports the restoration of growth dynamics in achondroplasia models, where FGFR3 mutations drive suppressed skeletal growth.

In preclinical studies, Vosoritide has demonstrated ability to restore longitudinal bone growth in both rodent and large animal models. It has been used to evaluate growth plate biology, bone elongation kinetics, and FGFR3 signaling modulation. Beyond classical achondroplasia research, Vosoritide also serves as a critical tool in studies of growth plate disorders, chondrodysplasia spectrum, and skeletal development mechanisms.

Manufactured under GMP standards with exceptional 99.89% purity, Vosoritide is supplied in a lyophilized format. It is suitable for a range of preclinical applications—from cell-based assays to in vivo administration in growth models. Each batch includes Certificate of Analysis (CoA) detailing identity confirmation, purity, and peptide integrity to support reproducible and compliant research.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action

Vosoritide simulates the activity of endogenous CNP but with enhanced stability. It binds to NPR-B, which is predominantly expressed in chondrocytes within the growth plate. Activation of NPR-B stimulates intracellular guanylate cyclase activity, elevating cGMP levels, which in turn activate PKG-dependent pathways. These signaling events counteract the inhibitory effects of aberrant FGFR3 signaling—a central driver in achondroplasia.

By modulating the growth plate environment, Vosoritide encourages chondrocyte proliferation, matrix synthesis, and longitudinal bone growth. In vitro and ex vivo bone explant studies demonstrate improved growth plate thickness, chondrocyte column organization, and restoration of proliferative zones in tissues influenced by FGFR3 mutations.

Research Applications

1. Achondroplasia & FPS (Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias)

Vosoritide is used to model functional rescue in growth plate chondrocytes derived from ACH patients or transgenic models. Research themes include corrections of bone length, assessment of cartilage matrix production, and evaluation of skeletal morphology responses.

2. Growth Plate Biology

Investigators can deploy Vosoritide to study fundamental determinants of endochondral ossification, mapping signaling cascades downstream of cGMP and profiling chondrocyte lineage progression.

3. FGFR3 Signaling Modulation

Use Vosoritide to dissect FGFR3-driven negative regulation of growth. It serves as a reference compound to test small molecules or biologics aimed at modulating FGFR3 or downstream nodes.

4. Skeletal Maturation & Comparative Models

Compare long bone growth responses across species (e.g., rodents, rabbits, large animals) to investigate dose–response, pharmacokinetics, and skeletal modeling responses.

5. Drug Combinatorial Studies

Combine Vosoritide with potential FGFR3 inhibitors, Wnt agonists, or IGF pathway modulators to assess synergistic or additive effects on growth plate dynamics.

Development & Formulation Notes

Reconstitution & Handling

• Reconstitution: Dissolve lyophilized Vosoritide in sterile water or buffer (pH 5–7) to achieve desired concentration (e.g., 1 mg/mL) under aseptic conditions.

• Stock Solutions: Prepare aliquots to minimize freeze–thaw cycles. Store stocks at –80 °C for long-term stability; working stocks may be stored at –20 °C for short-term use.

• Solvent Carriers: Small percentage of BSA or glycerol ( 5%) may improve handling and minimize adsorption in dilute solutions.

Dosing & Bioactivity

• In rodent models, effective dosing ranges can vary (commonly 0.5 to 2 mg/kg daily, subcutaneous). Dose responses should be empirically calibrated.

• Confirm biological activity by measuring cGMP production in chondrocyte cell lines or by quantifying growth plate histology/morphometry.

Formulation for in vivo studies

• Review osmolarity and pH for injection-grade preparations; use isotonic buffers and sterile filtration.

• Evaluate potential for sustained-release formulations or bulked micronized carriers if modulated dosing is desirable.

Analytical Validation

• Confirm purity and identity of reconstituted solution via HPLC and/or mass spectrometry if method development requires high-confidence validation.

• Monitor storage stability by periodic sampling and analytical validation.

Documentation & Quality Control

Each lot of Vosoritide comes with a full CoA, including details such as peptide sequence confirmation, purity percentage, molecular weight data, and recommended storage conditions. Analytical records support reproducibility and audit readiness.

Disclaimer

Vosoritide (BMN 111) is intended exclusively for laboratory research use only. This product is not for diagnostic, therapeutic, or clinical use in humans or animals. All usage must comply with institutional safety policies and applicable regulations. The user assumes full responsibility for compliance with safety, regulatory, and ethical standards. Any observations, claims, or results generated with Vosoritide do not constitute medical or therapeutic recommendations.

Keywords

Vosoritide; BMN 111; CNP analogue; NPR-B agonist; FGFR3 inhibitor; achondroplasia research; dwarfism model; growth plate peptide; GMP-grade peptide for growth studies; CAS 1480724-61-5; endochondral ossification modulator; chondrodysplasia research; skeletal growth compound.CAS 1480724-61-5.

Packaging & Availability

• Standard Sizes: 1 mg, 5 mg, 10 mg vials; custom quantities available upon request

• Bulk Orders: Multi-gram and custom packing with scheduled shipment options

• Documentation Package: Each lot includes CoA (with HPLC/MS data) and recommended reconstitution protocols for streamlined lab onboarding